Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 6
1948 2
1952 1
1953 4
1954 5
1955 8
1956 4
1957 7
1958 3
1959 2
1960 7
1961 5
1962 8
1963 7
1964 10
1965 8
1970 1
1971 7
1972 82
1973 107
1974 36
1975 30
1976 23
1977 13
1978 14
1979 20
1980 16
1981 8
1982 15
1983 10
1984 18
1985 16
1986 14
1987 14
1988 13
1989 15
1990 20
1991 40
1992 42
1993 39
1994 24
1995 18
1996 22
1997 14
1998 18
1999 15
2000 31
2001 22
2002 41
2003 31
2004 51
2005 51
2006 62
2007 76
2008 75
2009 75
2010 83
2011 132
2012 153
2013 143
2014 181
2015 200
2016 157
2017 170
2018 150
2019 83
2020 8
Text availability
Article attribute
Article type
Publication date

Search Results

2,508 results
Results by year
Filters applied: . Clear all
Page 1
Premenstrual disorders.
Yonkers KA, Simoni MK. Yonkers KA, et al. Am J Obstet Gynecol. 2018 Jan;218(1):68-74. doi: 10.1016/j.ajog.2017.05.045. Epub 2017 May 29. Am J Obstet Gynecol. 2018. PMID: 28571724 Review.
Metastatic Prostate Cancer.
Sartor O, de Bono JS. Sartor O, et al. N Engl J Med. 2018 Feb 15;378(7):645-657. doi: 10.1056/NEJMra1701695. Epub 2018 Feb 7. N Engl J Med. 2018. PMID: 29412780 Review. No abstract available.
Genomic correlates of clinical outcome in advanced prostate cancer.
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL. Abida W, et al. Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6. Proc Natl Acad Sci U S A. 2019. PMID: 31061129 Free PMC article.
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV. Luo J, et al. Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16. Eur Urol. 2018. PMID: 29258679 Free PMC article. Review.
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Szmulewitz RZ, et al. J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28. J Clin Oncol. 2018. PMID: 29590007 Free PMC article. Clinical Trial.
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN. Annala M, et al. Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24. Cancer Discov. 2018. PMID: 29367197 Free article. Clinical Trial.
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F. Clarke N, et al. Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4. Lancet Oncol. 2018. PMID: 29880291 Clinical Trial.
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF; STOPCaP Abiraterone Collaborators. Rydzewska LHM, et al. Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8. Eur J Cancer. 2017. PMID: 28800492 Free PMC article. Review.
2,508 results
Jump to page
Feedback